Scinai Immunotherapeutics Ltd.

About Scinai Immunotherapeutics Ltd.

Scinai Immunotherapeutics is a biopharmaceutical company focused on developing, manufacturing, and commercializing innovative inflammation and immunology (I&I) biological products primarily for the treatment of autoimmune and infectious diseases. They also provide CDMO (Contract Development and Manufacturing Organization) services through their Scinai BioServices business unit, supporting pharmaceutical and biotech companies in drug development and manufacturing.

Products & Services

Inflammation and Immunology (I&I) Biological Products:Innovative biological products targeting autoimmune and infectious diseases, including alpaca-derived nanosized antibodies (NanoAbs or VHH-antibodies) for conditions like psoriasis and asthma, addressing large markets with unmet needs.

CDMO BioServices:Boutique services for pharmaceutical and biotech companies, including process development, scale-up, analytical methods development, cGMP manufacturing, aseptic processing, and quality assurance for nonclinical and clinical studies.

Specialties

Inflammation and Immunology (I&I) Biological Products NanoAbs (Nanosized Antibodies) Development Autoimmune and Infectious Disease Treatments CDMO Services cGMP Manufacturing Process Development and Scale-Up Analytical Methods Development

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Grant T: - FT: Grant	A: 246000 MR: - FA: NIS 809,000 FAN: 246000	D: 2025-10-06 FD: 2025-10-06	1 investors
2	RT: Equity T: - FT: Equity	A: 1380000 MR: - FA: 1.38 million FAN: 1380000	D: 2025-06-12 FD: 2025-06-12	1 investors
3	RT: Standby Equity Purchase Agreement T: - FT: Standby Equity Purchase Agreement	A: 10000000 MR: - FA: $10 million FAN: 10000000	D: 2025-03-05 FD: 2025-03-05	1 investors
4	RT: Debt Conversion to Preferred Equity T: - FT: Debt Conversion to Preferred Equity	A: 29000000 MR: - FA: EUR 26.6 million (approximately $29 million) FAN: 29000000	D: 2024-08-21 FD: 2024-08-21	1 investors
5	RT: Private Equity T: - FT: Private Equity	A: 2000000 MR: - FA: 2 million FAN: 2000000	D: 2024-08-20 FD: 2024-08-20	1 investors
6	RT: Debt Restructuring T: - FT: Debt Restructuring	A: 29000000 MR: - FA: approximately $29 million FAN: 29000000	D: 2024-08-13 FD: 2024-08-13	1 investors
7	RT: Debt-to-Equity Conversion T: - FT: Debt-to-Equity Conversion	A: 28000000 MR: - FA: approximately $28 million FAN: 28000000	D: 2024-07-08 FD: 2024-07-08	1 investors
8	RT: Debt Conversion T: - FT: Debt Conversion	A: 27600000 MR: - FA: approximately $27.6 million FAN: 27600000	D: 2024-06-13 FD: 2024-06-13	1 investors
9	RT: Warrant Exercise T: - FT: Warrant Exercise	A: 1690000 MR: - FA: 1.69 million FAN: 1690000	D: 2024-01-04 FD: 2024-01-04	-
10	RT: Warrant Exercise T: - FT: Warrant Exercise	A: 1690000 MR: - FA: $1.69 million FAN: 1690000	D: 2023-12-29 FD: 2023-12-29	-
11	RT: Debt T: - FT: Debt	A: 24000000 MR: - FA: €24 million FAN: 24000000	D: 2023-11-29 FD: 2023-11-29	1 investors
12	RT: Grant T: - FT: Grant	A: 900000 MR: - FA: ILS 3,536,939 (approximately US$900,000) FAN: 900000	D: 2023-11-06 FD: 2023-11-06	1 investors
13	RT: Debt T: - FT: Debt	A: 24000000 MR: - FA: €24 million FAN: 24000000	D: 2023-10-31 FD: 2023-10-31	1 investors

Grant Latest

2025-10-06

$246K

1 investor (Pro only)

Equity 2025-06-12

$1.4M

Standby Equity Purchase Agreement 2025-03-05

$10.0M

View 12 more funding rounds with Pro

Unlock Full Funding History

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

A

Amir Reichman

CEO

T

Tamar Ben-Yedidia

CSO

E

Elad Mark

COO

D

Dalit Weinstein Fischer

CTO

U

Uri Ben-or

CFO

M

Merav Kamensky

Head of Quality Control

View 18 more team members with Pro

Unlock Full Team Directory

Recent News